188 related articles for article (PubMed ID: 37031300)
21. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
23. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
Zhao Y; Morgan MA; Sun Y
Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
[TBL] [Abstract][Full Text] [Related]
25. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVĪ51 oncolytic virotherapy.
Wong B; Bergeron A; Maznyi G; Ng K; Jirovec A; Birdi HK; Serrano D; Spinelli M; Thomson M; Taha Z; Alwithenani A; Chen A; Lorimer I; Vanderhyden B; Arulanandam R; Diallo JS
Mol Ther; 2023 Nov; 31(11):3176-3192. PubMed ID: 37766429
[TBL] [Abstract][Full Text] [Related]
26. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
Zhou H; Lu J; Yang CY; Sun Y; Wang S
Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
[TBL] [Abstract][Full Text] [Related]
27. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Paiva C; Godbersen JC; Rowland T; Danilova OV; Danes C; Berger A; Danilov AV
Oncotarget; 2017 Mar; 8(13):21128-21139. PubMed ID: 28177892
[TBL] [Abstract][Full Text] [Related]
28. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
Zhou W; Xu J; Tan M; Li H; Li H; Wei W; Sun Y
Mol Cell; 2018 Jun; 70(6):1008-1024.e6. PubMed ID: 29932898
[TBL] [Abstract][Full Text] [Related]
29. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
[TBL] [Abstract][Full Text] [Related]
31. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O; Kjellin H; Juhlin CC; Pan Y; Vesterlund M; Ghaderi M; Yousef A; Andersson-Sand H; Kharaziha P; Caramuta S; Kjellman M; Zedenius J; Larsson C; Orre LM
Oncogene; 2019 Oct; 38(43):6881-6897. PubMed ID: 31406256
[TBL] [Abstract][Full Text] [Related]
32. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
33. Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.
Torka P; Mavis C; Kothari S; Belliotti S; Gu J; Sundaram S; Barth M; Hernandez-Ilizaliturri FJ
EJHaem; 2020 Jul; 1(1):122-132. PubMed ID: 33073261
[TBL] [Abstract][Full Text] [Related]
34. The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice.
Yu H; Luo H; Chang L; Wang S; Geng X; Kang L; Zhong Y; Cao Y; Wang R; Yang X; Zhu Y; Shi MJ; Hu Y; Liu Z; Yin X; Ran Y; Yang H; Fan W; Zhao BQ
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35101976
[TBL] [Abstract][Full Text] [Related]
35. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
[TBL] [Abstract][Full Text] [Related]
36. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
[TBL] [Abstract][Full Text] [Related]
37. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
Picco G; Petti C; Sassi F; Grillone K; Migliardi G; Rossi T; Isella C; Di Nicolantonio F; Sarotto I; Sapino A; Bardelli A; Trusolino L; Bertotti A; Medico E
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27771609
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Luo Z; Pan Y; Jeong LS; Liu J; Jia L
Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
